This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms.
The study, which took place at 20 sites, investigated SNG001 in 134 adult asthma patients, representing 'mild-moderate' through to 'severe' asthmatics, who caught a cold. Patients with 'difficult to treat' asthma - approximately half of the patients in the trial - benefitted significantly from SNG001 treatment. This category of patient is estimated to represent between 10 per cent and 20 per cent of all adult asthma sufferers.
Results showed that SNG001 prevented asthma symptoms from getting worse during the first week of infection and treatment. There was a 65 per cent reduction in the number of patients experiencing moderate exacerbations during the treatment period and patients who were treated with the placebo had greater loss in lung function, as measured by morning peak expiratory flow rate, a measure of lung function.
Professor Stephen Holgate of the University of Southampton says: “This is a really promising breakthrough for the future treatment of asthma and one of the most exciting developments that I have seen in years. This is the first clinical study which appears to demonstrate that, by boosting the antiviral defences of the lungs of asthmatics rather than trying to inhibit rapidly evolving viruses, we can limit the adverse effects of viral infection significantly to prevent worsening of asthma symptoms in a high risk group of patients.”
This trial is an important milestone in the development of our SNG001 programme to today's exciting results in this 'real world' asthma study. Not only have we established the potential of SNG001 as a novel treatment for viral exacerbations in difficult to treat asthma but also a crucial link between viral infection, asthma symptoms and severity of disease.
"These impressive findings across different endpoints, together with the accumulating body of evidence we have generated for other respiratory viruses such as influenza, Swine and Bird flu, and respiratory syncytial virus (RSV), strongly suggest that SNG001 has the potential to be used as a powerful broad spectrum antiviral respiratory drug in lung diseases such as COPD and pandemic flu," says Holgate.
MEDICA.de; Source: University of Southampton